Calidi Biotherapeutics (CLDI) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free CLDI Stock Alerts $0.19 -0.11 (-36.67%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 3:16 AM | americanbankingnews.comCalidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Price Down 35%May 31 at 8:51 AM | businesswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsMay 17, 2024 | finanznachrichten.deCalidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone Show on Bloomberg TVMay 15, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024May 14, 2024 | businesswire.comCalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 1, 2024 | businesswire.comCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingApril 23, 2024 | finance.yahoo.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24April 23, 2024 | businesswire.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24April 19, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingApril 16, 2024 | msn.comWhy Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%April 16, 2024 | investorplace.comWhy Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?April 16, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingApril 9, 2024 | finance.yahoo.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024April 9, 2024 | businesswire.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024March 16, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023March 15, 2024 | businesswire.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsMarch 11, 2024 | businesswire.comCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerFebruary 12, 2024 | finance.yahoo.comCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceFebruary 8, 2024 | msn.comCalidi Biotherapeutics Shares Informal Financial UpdateFebruary 2, 2024 | msn.comCalidi Biotherapeutics Conducts Private Equity SaleJanuary 9, 2024 | uk.finance.yahoo.comCalidi Biotherapeutics, Inc. (CLDI)January 8, 2024 | finance.yahoo.comCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardDecember 12, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of DirectorsDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023December 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial OfficerDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Key Leadership Promotions and New Board AppointmentDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)December 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. CLDI Media Mentions By Week CLDI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼-0.330.76▲Average Medical News Sentiment CLDI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼31▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aligos Therapeutics News IN8bio News Cyclo Therapeutics News OKYO Pharma News Brainstorm Cell Therapeutics News Achilles Therapeutics News Quince Therapeutics News NKGen Biotech News Surrozen News MiNK Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:CLDI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.